Name : PARK2(Ser101) Antibody
Supplier : BIOSS PRIMARY UNCONJUGATED ANTIBODIES
Price :281
SKU : GEN3130331561
| Long name | PARK2(Ser101) Primary Polyclonal Antibody |
| Also known as | PARK2(Ser101) PAb |
| Category | Primary Antibodies |
| Conjugation | Unconjugated |
| Target Antigen | PARK2 Ser101 |
| Specificity | This is a highly specific antibody against PARK2 Ser101 |
| Modification(s) | Phosphorylation |
| Modification site(s) | Ser101 |
| Clonality | Polyclonal antibody |
| Clone number | Polyclonal antibody |
| Concentration | 1ug per 1ul |
| Source | KLH conjugated synthetic phosphopeptide derived from human PARK2 around the phosphorylation site of Ser101 |
| Gene ID number | 5071 |
| Tested Applications | IF(IHC-P), IHC-P, WB |
| Recommended dilutions | IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity | Human |
| Cross reactive species details | not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen | Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin, Parkin, The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions), the second most common neurodegenerative disease after Alzheimer's Disease, thus targeting them for degradation by the proteasome, Parkinson's Disease |
| Purification method | This antibody was purified via Protein A |
| Storage conditions | 50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names | AR JP, E3 ubiquitin protein ligase parkin, FRA6E, LPRS 2, LPRS2, PARK 2, PARK2, PDJ, PRKN, PRKN 2, PRKN2, Parkinson disease autosomal recessive juvenile 2, Parkinson disease protein 2, Parkinson juvenile disease protein 2, Ubiquitin E3 ligase PRKN, PARK2phospho S101 |
| Properties | C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target | PARK2(Ser101) |
| Short name | PARK2(Ser101) Antibody |
| Technique | antibodies against human proteins, antibodies for, Antibody |
| Alternative name | PARK2(Ser101) (Antibody to) |
| Alternative technique | antibodies |
| Identity | 8607 |
| Gene | PARK2 |
| Long gene name | parkin RBR E3 ubiquitin protein ligase |
| Synonyms gene name | E3 ubiquitin protein ligase (parkin) , Parkinson disease (autosomal recessive, juvenile) 2, parkin parkinson protein 2 |
| Synonyms | PDJ AR-JP parkin PRKN |
| Synonyms name | E3 ubiquitin ligase |
| Locus | 6q26 |
| Discovery year | 1997-08-18 |
| Entrez gene record | 5071 |
| Pubmed identfication | 9560156 9570960 |
| Classification | Parkinson disease associated genes RBR E3 ubiquitin ligases |
| Havana BLAST/BLAT | OTTHUMG00000015970 |
| Locus Specific Databases | Parkinson', s disease Mutation Database |